Potential role of immunotherapy in advanced non-small-cell lung cancer

被引：45

作者：

de Mello, Ramon Andrade ^{[1
,2
,3
]}

Veloso, Ana Flavia ^{[4
]}

Catarina, Paulo Esrom ^{[4
]}

Nadine, Sara ^{[5
]}

Antoniou, Georgios ^{[6
]}

机构：

[1] Univ Algarve, Dept Biomed Sci & Med, Gambelas Campus,Ala Nascente,Bldg 7,3rd Floor, P-8005139 Faro, Portugal

[2] Univ Porto, Fac Med, Oporto, Portugal

[3] Inst Canc Ceara, Cearense Sch Oncol, Res Ctr, Fortaleza, Ceara, Brazil

[4] State Univ Ceara UECE, Sch Med, Oncol & Hematol League, Fortaleza, Ceara, Brazil

[5] Univ Porto, ICBAS, Oporto, Portugal

[6] Royal Marsden NHS Fdn Trust, Dept Med Oncol, London, England

来源：

ONCOTARGETS AND THERAPY | 2017年 / 10卷

关键词：

immunotherapy; non-small-cell lung cancer; nivolumab; pembrolizumab; ipilimumab; clinical trials; PD1; PDL1; CTLA4; IMMUNE CHECKPOINT INHIBITORS; IFN-GAMMA; NIVOLUMAB; IMMUNOSURVEILLANCE; ANTI-PD-1; ESCAPE; SUPPRESSION; MANAGEMENT; PATHWAYS; AGENTS;

D O I：

10.2147/OTT.S90459

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD- 1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework.

引用

页码：21 / 30

页数：10

共 56 条

[1] The coming of age of tumour immunotherapy [J].

Ada, G .

IMMUNOLOGY AND CELL BIOLOGY, 1999, 77 (02) :180-185

[2] A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker [J].

Aguiar, Pedro N., Jr. ;

Santoro, Ilka Lopes ;

Tadokoro, Hakaru ;

Lopes, Gilberto de Lima ;

Filardi, Bruno Andraus ;

Oliveira, Pedro ;

Castelo-Branco, Pedro ;

Mountzios, Giannis ;

de Mello, Ramon Andrade .

IMMUNOTHERAPY, 2016, 8 (09) :1011-1019

[3] Best practice in the treatment of advanced squamous cell lung cancer [J].

Ang, Yvonne L. E. ;

Tan, Hon-Lyn ;

Soo, Ross A. .

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) :224-235

[4]

[Anonymous], 2015, J IMMUNOTHER CANC

[5]

[Anonymous], EUR J CANC

[6] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. [J].

Antonia, Scott Joseph ;

Gettinger, Scott N. ;

Chow, Laura Quan Man ;

Juergens, Rosalyn A. ;

Borghaei, Hossein ;

Shen, Yun ;

Harbison, Christopher ;

Chen, Allen C. ;

Ready, Neal ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review [J].

Brown, T. ;

Pilkington, G. ;

Boland, A. ;

Oyee, J. ;

Smith, C. Tudur ;

Dundar, Y. ;

Richards, E. ;

Yang, R. ;

Dickson, R. .

HEALTH TECHNOLOGY ASSESSMENT, 2013, 17 (06) :1-+

[9] CANCER - A BIOLOGICAL APPROACH .3. VIRUSES ASSOCIATED WITH NEOPLASTIC CONDITIONS [J].

BURNET, M .

BMJ-BRITISH MEDICAL JOURNAL, 1957, 1 (APR13) :841-846

[10] Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial [J].

Butts, Charles ;

Socinski, Mark A. ;

Mitchell, Paul L. ;

Thatcher, Nick ;

Havel, Libor ;

Krzakowski, Maciej ;

Nawrocki, Sergiusz ;

Ciuleanu, Tudor-Eliade ;

Bosquee, Lionel ;

Manuel Trigo, Jose ;

Spira, Alexander ;

Tremblay, Lise ;

Nyman, Jan ;

Ramlau, Rodryg ;

Wickart-Johansson, Gun ;

Ellis, Peter ;

Gladkov, Oleg ;

Pereira, Jose Rodrigues ;

Eberhardt, Wilfried Ernst Erich ;

Helwig, Christoph ;

Schroeder, Andreas ;

Shepherd, Frances A. .

LANCET ONCOLOGY, 2014, 15 (01) :59-68

← 1 2 3 4 5 6 →